Last edition
News about "overt hepatic encephalopathy (HE) recurrence"
Biocon and Carnegie Secure Tentative FDA Approval for Rifaximin Tablets
Biocon Pharma, a wholly owned subsidiary of Biocon Ltd., in partnership with Carnegie Pharmaceuticals, has received tentative approval from the US Food and Drug Administration (US FDA) for its Abbreviated New Drug Application (ANDA) for Rifaximin Tablets, 550 mg.
Overt Hepatic Encephalopathy (HE) Recurrence | 07/10/2025 | By Dineshwori
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members